13F Holdings
中文EN

NPHC NUTRA PHARMA CORP

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1119643 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-49.0%
TTM net income YoY-255.0%
TTM EPS YoY—
Revenue 3-yr CAGR-31.6%
Net income 3-yr CAGR—

Margins

Gross margin64.8%
Operating margin-1,017.8%
Net margin-3,370.6%
FCF margin—
EBITDA margin-1,011.4%

Returns

ROE—
ROA-731.5%
ROIC (approx.)—
Asset turnover0.22x

Leverage & solvency

Liabilities / assets3,505.0%
Debt / equity—
Current ratio0.02x
Interest coverage-68.24x

Cash quality & payout

Operating cash flow / net income0.19x
Accruals ratio-589.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$257,612$246,309$205,564$145,800$97,735
Cost of revenue$183,679$240,557$177,525$162,842$41,268
Gross profit$196,628$247,323$396,455$249,022$8,467
SG&A expense—$1.13M$1.18M$2.08M$1.93M
Operating income-$1.46M-$878,421-$886,979-$1.91M-$1.99M
Interest expense$22,870$21,237$18,815$17,141$18,246
Pretax income-$2.05M-$1.29M-$1.39M$8.18M-$13.10M
Net income-$2.05M-$1.29M-$1.39M$8.18M-$13.10M
EBITDA-$1.45M-$870,981-$868,791-$1.88M-$1.98M
EPS (basic)0.000.000.000.00-0.00
EPS (diluted)0.000.000.000.00-0.00
Weighted avg. shares (diluted)7.78B7.67B7.61B19.10B7.23B
Balance sheet
Cash & equivalents$12,181$36,447$0$0$90,910
Short-term investments$17,600$17,600$35,200——
Receivables——$22,433$21,664$45,998
Inventory$19,535$17,696$19,544$23,866$31,289
Current assets$459,583$374,837$314,060$333,577$533,827
PP&E, net$25,805$10,402$17,842$80,012$44,701
Total assets$622,601$599,495$640,397$754,913$780,022
Current liabilities$17.31M$15.27M$14.17M$12.70M$21.14M
Short-term debt$9.62M$8.49M$8.33M$7.93M$7.60M
Long-term debt$136,644$140,217$143,657$8.19M—
Total debt$9.76M$8.63M$8.47M$16.12M—
Total liabilities$17.45M$15.41M$14.41M$13.13M$21.66M
Shareholders' equity-$16.83M-$14.81M-$13.77M-$12.38M-$20.88M
Net debt$9.75M$8.59M$8.47M$16.12M—
Shares outstanding7.10B7.10B7.06B7.04B6.77B
Cash flow statement
Operating cash flow-$1.16M-$423,959-$550,036-$762,432-$1.74M
Capital expenditure$26,052——$57,993$39,043
Free cash flow-$1.19M——-$820,425-$1.78M
Investing cash flow-$51,052$41,300$117,355$27,306-$293,543
Financing cash flow$1.19M$419,106$432,681$644,216$2.13M
Depreciation & amortization$10,649$7,440$18,188$22,682$9,084
Stock-based compensation$26,667——$20,500$153,500

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.